Systemic administration is targeted to specific cells in the bone marrow
Elegance + precision: A novel framework for treating severe blood disorders
We are redefining treatment for severe hematologic diseases by extending the applicability of a validated therapeutic modality into the bone marrow. By targeting the appropriate payload to developing bone marrow cells that drive these diseases, we aim to enhance efficacy and safety and achieve functional cures. Our mission is to create best-in-class therapies that are not only transformative but accessible to patients around the globe.
A homing beacon in the bone marrow
Bone marrow must continuously generate blood and immune cells. This constant growth and proliferation demand large amounts of iron, which is essential to energy production, DNA synthesis and other cellular processes. To meet this need, bone marrow cells express the transferrin receptor (TfR1), which mediates iron uptake, at markedly higher levels than most other human cells.
Opportunity to address disease drivers across red and white blood cell lineages
We are leveraging engineered antibodies targeting TfR1 to deliver therapeutic payloads to blood and immune cells for the treatment of hematologic disorders such as sickle cell disease and beta thalassemia, as well as other genetically defined diseases arising in the bone marrow.
Engineering antibody bioconjugates
Our de-risked, first-in-class bone marrow technology platform, gives us the precision and flexibility to interrogate the hematological disease space broadly with therapeutics tailored to treat a wide diversity of diseases. It can be adapted to target different cells in the bone marrow with a variety of payloads, including oligonucleotides, siRNA, enzymes and small molecules.
We leverage this proprietary platform to develop our TfR1 antibody bioconjugates (TAB). TABs consist of a TfR1 binder, optimized linker and therapeutic payload, and are engineered to maximize efficiency, cell entry and stability.
Learn about our programs
Pipeline & Programs